Sientra Inc (NASDAQ:SIEN) – Research analysts at Svb Leerink issued their Q1 2019 earnings estimates for shares of Sientra in a research note issued on Wednesday, March 13th. Svb Leerink analyst R. Newitter forecasts that the medical instruments supplier will post earnings per share of ($0.81) for the quarter. Svb Leerink also issued estimates for Sientra’s Q2 2019 earnings at ($0.74) EPS, Q3 2019 earnings at ($0.73) EPS, Q4 2019 earnings at ($0.63) EPS, FY2019 earnings at ($2.90) EPS and FY2020 earnings at ($2.00) EPS.
Sientra (NASDAQ:SIEN) last posted its earnings results on Tuesday, March 12th. The medical instruments supplier reported ($0.86) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.67) by ($0.19). The business had revenue of $19.02 million for the quarter, compared to the consensus estimate of $18.87 million. Sientra had a negative return on equity of 123.50% and a negative net margin of 121.28%.
Other analysts also recently issued research reports about the company. Maxim Group reissued a “buy” rating and issued a $20.00 price target on shares of Sientra in a research note on Monday, February 11th. ValuEngine downgraded Sientra from a “strong-buy” rating to a “buy” rating in a research note on Thursday, January 24th. William Blair downgraded Sientra from an “outperform” rating to a “market perform” rating in a research note on Wednesday. Leerink Swann dropped their price target on Sientra from $22.00 to $18.00 in a research note on Wednesday. Finally, BidaskClub downgraded Sientra from a “sell” rating to a “strong sell” rating in a research note on Tuesday, December 18th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and eight have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $20.44.
SIEN stock opened at $8.84 on Friday. The company has a debt-to-equity ratio of 0.36, a quick ratio of 2.34 and a current ratio of 2.77. The stock has a market cap of $325.46 million, a price-to-earnings ratio of -2.72 and a beta of -0.04. Sientra has a 1-year low of $7.74 and a 1-year high of $26.79.
Several large investors have recently added to or reduced their stakes in the stock. Geode Capital Management LLC increased its position in shares of Sientra by 10.0% in the fourth quarter. Geode Capital Management LLC now owns 254,747 shares of the medical instruments supplier’s stock valued at $3,237,000 after acquiring an additional 23,117 shares during the last quarter. Dimensional Fund Advisors LP acquired a new stake in shares of Sientra in the fourth quarter valued at about $135,000. HRT Financial LLC acquired a new stake in shares of Sientra in the fourth quarter valued at about $157,000. Millennium Management LLC increased its position in shares of Sientra by 117.6% in the fourth quarter. Millennium Management LLC now owns 966,106 shares of the medical instruments supplier’s stock valued at $12,279,000 after acquiring an additional 522,153 shares during the last quarter. Finally, Metropolitan Life Insurance Co. NY increased its position in shares of Sientra by 356.6% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 8,191 shares of the medical instruments supplier’s stock valued at $104,000 after acquiring an additional 6,397 shares during the last quarter. 92.79% of the stock is currently owned by institutional investors and hedge funds.
Sientra Company Profile
Sientra, Inc, a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. It operates through two segments, Breast Products and miraDry. The company offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names.
Further Reading: Depreciation
Receive News & Ratings for Sientra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra and related companies with MarketBeat.com's FREE daily email newsletter.